Brian H. Kushner, Shakeel Modak, Kim Kramer, Ellen M. Basu, Stephen S. Roberts and Nai-Kong V. Cheung Ifosfamide, carboplatin, and etoposide for neuroblastoma Cancer 119
Version of Record online: 5 SEP 2012 | DOI: 10.1002/cncr.27783
Antineuroblastoma activity and tolerable toxicity are evident both in a large experience with a high-dose ifosfamide, carboplatin, and etoposide regimen in 74 patients with resistant disease and in a literature review. The findings support the use of this triple-drug combination in patients with neuroblastoma.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field